ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Cancer Treat Rev · 2025-12-16

Systematic review of 23 studies in HR+/HER2- breast cancer: CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone raised grade 3/4 QTc prolongation risk (RR 1.83, driven by ribociclib) and VTE risk (RR 2.57, highest with abemaciclib).

Meta-analysisn = 23 studies
Hoo et al. Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.